CD82 (gene)

CD82 molecule
Identifiers
Symbols CD82 ; 4F9; C33; GR15; IA4; KAI1; R2; SAR2; ST6; TSPAN27
External IDs OMIM: 600623 MGI: 104651 HomoloGene: 20512 GeneCards: CD82 Gene
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 3732 12521
Ensembl ENSG00000085117 ENSMUSG00000027215
UniProt P27701 P40237
RefSeq (mRNA) NM_001024844 NM_001136055
RefSeq (protein) NP_001020015 NP_001129527
Location (UCSC) Chr 11:
44.56 – 44.62 Mb		 Chr 2:
93.42 – 93.46 Mb
PubMed search

CD82 (Cluster of Differentiation 82) is a human protein encoded by the CD82 gene.[1]

This metastasis suppressor gene product is a membrane glycoprotein that is a member of the transmembrane 4 superfamily. Expression of this gene has been shown to be downregulated in tumor progression of human cancers and can be activated by p53 through a consensus binding sequence in the promoter. Its expression and that of p53 are strongly correlated, and the loss of expression of these two proteins is associated with poor survival for prostate cancer patients. Two alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.[1]

Interactions

CD82 (gene) has been shown to interact with CD19,[2][3] CD63[4] and CD234

See also

References

  1. 1 2 "Entrez Gene: CD82 CD82 molecule".
  2. ↑ Imai, T; Kakizaki M; Nishimura M; Yoshie O (August 1995). "Molecular analyses of the association of CD4 with two members of the transmembrane 4 superfamily, CD81 and CD82". J. Immunol. (UNITED STATES) 155 (3): 1229–39. ISSN 0022-1767. PMID 7636191.
  3. ↑ Horváth, G; Serru V; Clay D; Billard M; Boucheix C; Rubinstein E (November 1998). "CD19 is linked to the integrin-associated tetraspans CD9, CD81, and CD82". J. Biol. Chem. (UNITED STATES) 273 (46): 30537–43. doi:10.1074/jbc.273.46.30537. ISSN 0021-9258. PMID 9804823.
  4. ↑ Hammond, C; Denzin L K; Pan M; Griffith J M; Geuze H J; Cresswell P (October 1998). "The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules". J. Immunol. (UNITED STATES) 161 (7): 3282–91. ISSN 0022-1767. PMID 9759843.

Further reading

  • Baek SH (2006). "A novel link between SUMO modification and cancer metastasis.". Cell Cycle 5 (14): 1492–5. doi:10.4161/cc.5.14.3008. PMID 16861889. 
  • Imai T, Fukudome K, Takagi S; et al. (1992). "C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63.". J. Immunol. 149 (9): 2879–86. PMID 1401919. 
  • Ichikawa T, Ichikawa Y, Dong J; et al. (1992). "Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11.". Cancer Res. 52 (12): 3486–90. PMID 1596907. 
  • Gaugitsch HW, Hofer E, Huber NE; et al. (1991). "A new superfamily of lymphoid and melanoma cell proteins with extensive homology to Schistosoma mansoni antigen Sm23.". Eur. J. Immunol. 21 (2): 377–83. doi:10.1002/eji.1830210219. PMID 1842498. 
  • Ichikawa T, Ichikawa Y, Isaacs JT (1991). "Genetic factors and suppression of metastatic ability of prostatic cancer.". Cancer Res. 51 (14): 3788–92. PMID 2065333. 
  • Imai T, Kakizaki M, Nishimura M, Yoshie O (1995). "Molecular analyses of the association of CD4 with two members of the transmembrane 4 superfamily, CD81 and CD82.". J. Immunol. 155 (3): 1229–39. PMID 7636191. 
  • Dong JT, Lamb PW, Rinker-Schaeffer CW; et al. (1995). "KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2.". Science 268 (5212): 884–6. doi:10.1126/science.7754374. PMID 7754374. 
  • Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.". Gene 138 (1-2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298. 
  • Mannion BA, Berditchevski F, Kraeft SK; et al. (1996). "Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associated with integrin alpha 4 beta 1 (CD49d/CD29).". J. Immunol. 157 (5): 2039–47. PMID 8757325. 
  • Szöllósi J, Horejsí V, Bene L; et al. (1996). "Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY.". J. Immunol. 157 (7): 2939–46. PMID 8816400. 
  • Dong JT, Isaacs WB, Barrett JC, Isaacs JT (1997). "Genomic organization of the human KAI1 metastasis-suppressor gene.". Genomics 41 (1): 25–32. doi:10.1006/geno.1997.4618. PMID 9126478. 
  • Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K; et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library.". Gene 200 (1-2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149. 
  • Hammond C, Denzin LK, Pan M; et al. (1998). "The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules.". J. Immunol. 161 (7): 3282–91. PMID 9759843. 
  • Horváth G, Serru V, Clay D; et al. (1998). "CD19 is linked to the integrin-associated tetraspans CD9, CD81, and CD82.". J. Biol. Chem. 273 (46): 30537–43. doi:10.1074/jbc.273.46.30537. PMID 9804823. 
  • Serru V, Le Naour F, Billard M; et al. (1999). "Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan interactions.". Biochem. J. 340 (1): 103–11. doi:10.1042/0264-6021:3400103. PMC 1220227. PMID 10229664. 
  • Lombardi DP, Geradts J, Foley JF; et al. (1999). "Loss of KAI1 expression in the progression of colorectal cancer.". Cancer Res. 59 (22): 5724–31. PMID 10582691. 
  • Shibagaki N, Hanada K, Yamashita H; et al. (2000). "Overexpression of CD82 on human T cells enhances LFA-1 / ICAM-1-mediated cell-cell adhesion: functional association between CD82 and LFA-1 in T cell activation.". Eur. J. Immunol. 29 (12): 4081–91. doi:10.1002/(SICI)1521-4141(199912)29:12<4081::AID-IMMU4081>3.0.CO;2-I. PMID 10602019. 
  • Nakamura K, Mitamura T, Takahashi T; et al. (2000). "Importance of the major extracellular domain of CD9 and the epidermal growth factor (EGF)-like domain of heparin-binding EGF-like growth factor for up-regulation of binding and activity.". J. Biol. Chem. 275 (24): 18284–90. doi:10.1074/jbc.M907971199. PMID 10749879. 
  • Odintsova E, Sugiura T, Berditchevski F (2001). "Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1.". Curr. Biol. 10 (16): 1009–12. doi:10.1016/S0960-9822(00)00652-7. PMID 10985391. 
  • Ono M, Handa K, Withers DA, Hakomori S (2001). "Glycosylation effect on membrane domain (GEM) involved in cell adhesion and motility: a preliminary note on functional alpha3, alpha5-CD82 glycosylation complex in ldlD 14 cells.". Biochem. Biophys. Res. Commun. 279 (3): 744–50. doi:10.1006/bbrc.2000.4030. PMID 11162423. 

External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.


This article is issued from Wikipedia - version of the Wednesday, April 29, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.